Oral Cancer Treatment Market Trends

Increase in prevalence of oral cancer to boost market growth

The rising prevalence of oral cancer is likely to support the growth of the Oral Cancer Treatment Market. According to the American Cancer Society, the incidence of oral and oropharyngeal cancer has been increasing in recent years. In 2021, an estimated 54,010 people in the United States will be diagnosed with oral cavity or oropharyngeal cancer, and an estimated 10,850 will die from the disease. The increasing prevalence of risk factors for oral cancer, such as smoking, alcohol consumption, and human papillomavirus (HPV) infection, is also driving the demand for oral cancer treatments.

Additionally, the availability of advanced technologies and treatments, such as surgery, radiation therapy, chemotherapy, and targeted therapy, is contributing to the growth of the Oral Cancer Treatment Market. Furthermore, the rising awareness about the importance of early detection and diagnosis of oral cancer is driving the demand for screening and diagnostic tests, such as biopsies, imaging tests, and blood tests. This is expected to further support the growth of the Oral Cancer Treatment Market, as early detection and treatment can improve the outcomes and survival rates for patients with oral cancer.

According to the National Cancer Institute, in the United States in 2021, there were an estimated 53,260 new cases of oral and oropharyngeal cancer and an estimated 10,750 deaths from these cancers.

Global geriatric population increase is anticipated to offer players in the dental caries treatment market with lucrative growth prospects. For instance, dentures, a lack of dexterity, a switch from complex to simple carbohydrates, and poor oral hygiene put the elderly at risk for developing root caries. According to the American Dental Association, older persons are more likely to develop root caries as a result of increased xerostomia-producing medication use as well as increased gingival recession, which exposes root surfaces. More than 50% of people 75 years and older have at least one tooth affected by root caries.

Dental technology developments are anticipated to provide companies in the dental caries treatment market with lucrative growth prospects. For instance, Pearl raised US$ 11 million in May 2019 to use AI to evaluate dental scans (Artificial Intelligence). According to the company, it will simplify tedious, repetitive operations, boost profits across dentistry, and—most notably the level of care by validating diagnoses and removing significant amounts of ambiguity from the dental equation.

The Global Oral Cancer Treatment Market Industry is poised for substantial growth, with projections indicating a market value of 2.04 USD Billion in 2024 and an anticipated increase to 3.87 USD Billion by 2035. This growth trajectory reflects a compound annual growth rate of 5.98% from 2025 to 2035. The market dynamics are influenced by various factors, including advancements in treatment technologies, increasing awareness, and government initiatives. These projections suggest a robust future for the industry, driven by ongoing research and development efforts aimed at improving patient outcomes and expanding access to care.

The aging population is contributing to the growth of the Global Oral Cancer Treatment Market Industry. As individuals age, the risk of developing oral cancer increases, necessitating effective treatment options. The demographic shift towards an older population is prompting healthcare systems to adapt and expand their services to meet the needs of this group. With the market projected to grow to 3.87 USD Billion by 2035, addressing the unique challenges faced by elderly patients, including comorbidities and treatment tolerability, will be crucial. This demographic trend underscores the importance of tailored treatment strategies in the evolving landscape of oral cancer care.

The Global Oral Cancer Treatment Market Industry is experiencing growth due to the increasing incidence of oral cancer worldwide. According to health statistics, the prevalence of oral cancer is on the rise, with an estimated 2.04 USD Billion market value in 2024. This increase is attributed to factors such as tobacco use, alcohol consumption, and the human papillomavirus (HPV). As awareness of oral cancer symptoms and risk factors grows, more individuals seek treatment, thereby driving demand for innovative therapies and interventions. The need for effective treatment options is likely to propel market expansion in the coming years.

Government initiatives aimed at combating oral cancer are fostering growth in the Global Oral Cancer Treatment Market Industry. Various countries are allocating funds for research, awareness campaigns, and treatment accessibility. These initiatives not only enhance public health infrastructure but also encourage the development of new therapies. As the market anticipates a compound annual growth rate of 5.98% from 2025 to 2035, government support is likely to play a pivotal role in driving innovation and improving treatment options for patients. This collaborative approach between governments and healthcare providers is essential for addressing the challenges posed by oral cancer.

Technological advancements in treatment modalities are significantly influencing the Global Oral Cancer Treatment Market Industry. Innovations such as targeted therapies, immunotherapies, and minimally invasive surgical techniques are enhancing treatment efficacy and patient outcomes. These advancements not only improve survival rates but also reduce recovery times, making treatments more appealing to patients. As the market is projected to reach 3.87 USD Billion by 2035, the integration of cutting-edge technologies is expected to play a crucial role in shaping treatment protocols and expanding access to care, ultimately benefiting patients and healthcare providers alike.

Increased awareness regarding oral cancer and the importance of early detection is a key driver for the Global Oral Cancer Treatment Market Industry. Public health initiatives and screening programs are being implemented globally to educate populations about risk factors and symptoms associated with oral cancer. These efforts are likely to lead to earlier diagnoses, which can significantly improve treatment outcomes. As more individuals participate in screening, the demand for effective treatment options will rise, contributing to the market's projected growth. The industry is expected to benefit from these initiatives as they promote proactive health behaviors.

Major market players are spending a lot of money on R&D to increase their product lines, which will help the oral cancer treatment market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the oral cancer treatment industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies adopted by manufacturers in the global oral cancer treatment industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, oral cancer treatment industry has provided medicine and treatment with some of the most significant benefits. The oral cancer treatment market major player such as Bristol-Myers Squibb Company (the U.S.), Merck & Co., Inc. (U.S.), Qilu Pharmaceutical Co., Ltd. (Asia Pacific) and others are working to expand the market demand by investing in research and development activities.

Bristol-Myers Squibb Company (BMS) is a global biopharmaceutical company that focuses on discovering, developing, and delivering innovative medicines for patients with serious diseases. BMS was founded in 1858 and is headquartered in New York City. BMS has a diverse portfolio of medicines that includes treatments for cancer, cardiovascular diseases, immunoscience, and fibrosis. Some of the company's most well-known drugs include Opdivo, Eliquis, Orencia, and Yervoy.

In 2020, Bristol Myers Squibb announced that the FDA had granted accelerated approval for its drug OPDIVO (nivolumab) for the treatment of patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. ESCC is a type of oral cancer that affects the lining of the esophagus.

Also, Merck & Co., Inc. (also known as MSD outside of the United States and Canada) is a global pharmaceutical company headquartered in New Jersey, USA. Merck is one of the largest pharmaceutical companies in the world, with a focus on developing, manufacturing, and marketing innovative medicines, vaccines, and animal health products. The company's areas of focus include oncology, vaccines, infectious diseases, neuroscience, and cardiovascular disease, among others. Merck is known for its research and development capabilities, as well as its commitment to advancing healthcare and improving patient outcomes.

In 2021, Merck announced that it had received FDA approval for KEYTRUDA (pembrolizumab) in combination with chemotherapy for the treatment of locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) carcinoma. GEJ cancer can be a form of oral cancer. Merck has also been involved in ongoing clinical trials for the treatment of oral cancer with KEYTRUDA.